Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

ŤAPUCHOVÁ Ivana PYTLIK Robert ŠIMARA Pavel TESAŘOVÁ Lenka KOUTNÁ Irena

Year of publication 2022
Type Article in Periodical
Magazine / Source Transplant Immunology
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.sciencedirect.com/science/article/pii/S0966327422000132
Doi http://dx.doi.org/10.1016/j.trim.2022.101539
Keywords Virus-specific T cells; Herpesviruses; Adoptive transfer; Cytomegalovirus; Resistance; Interferon gamma; Immunotherapy
Description Herpesviruses can either cause primary infection or may get reactivated after both hematopoietic cell and solid organ transplantations. In general, viral infections increase post-transplant morbidity and mortality. Prophylactic, preemptive, or therapeutically administered antiviral drugs may be associated with serious side effects and may induce viral resistance. Virus-specific T cells represent a valuable addition to antiviral treatment, with high rates of response and minimal side effects. Even low numbers of virus-specific T cells manufactured by direct selection methods can reconstitute virus-specific immunity after transplantation and control viral replication. Virus-specific T cells belong to the advanced therapy medicinal products, and their production is regulated by appropriate legislation; also, strict safety regulations are required to minimize their side effects.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.